Advertisement: Bar Ellison mid banner property
Advertisement: Excalibur Healthcare mid banner
Advertisement: SATAVIA mid banner
Advertisement: Simpsons Creative
Cambridgeand mid banner advertisement
ARM Innovation Hub
Advertisement: CJBS mid banner
Advertisement: TTP
Mid banner advertisement: BDO
Advertisement: Kao Data Centre mid banner
Advertisement: EBCam mid banner
Advertisement: Wild Knight Vodka
Barr Ellison Solicitors – commercial property
Advertisement: RSM mid banner
Advertisement: Cambridge Network mid banner
Advertisement: S-Tech mid banner 3
Advertisement: partnersand mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: Mogrify mid banner
5 May, 2022 - 12:38 By Tony Quested

Mologic and Alamar team up to fight future threats from Covid

With Covid causing chaos in China and variants reported in other territories around the world, a UK-US alliance is ramping capability with production of refined rapid diagnostic tests.

Mologic in Bedford UK and Maine in the US and Alamar Biosciences in California are partnering on the project.

The collaboration will utilise Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.

Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (COVIOS and COVIGO for personal self-testing) based on its lateral flow assay technology, utilising high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen. 

Second generation tests with even greater sensitivity are now in development leveraging the latest generation of engineered antibodies with ultra-high affinity, discovered through Alamar’s proprietary Attobody™ platform together with Mologic’s novel electronic lateral flow immunoassay (eLFIA) technology.

Professor Paul Davis, chief scientific officer & co-founder of Mologic, said: “We are very pleased with the increased sensitivity attainable with Alamar antibodies, especially in view of the speed with which they can be developed. 

“We look forward to continuing our collaboration to create the road map for unprecedented speed of response to new pandemic threats of whatever origin. 

“Fast-track discovery and deployment of antibodies with the highest possible affinity and specificity will be the central pillar of this new Pandemic Preparedness, very much aligning with Mologic’s mission to better enable humanity to cope with the long-term presence of COVID-19.”

Dr Yuling Luo, founder, chairman & CEO of Alamar, added: “Rapid and highly sensitive COVID-19 detection will remain an essential global health challenge in the coming years and we must learn from the global COVID-19 experience to ensure a better, robust Pandemic Preparedness. We are excited to continue working with Mologic to meet these needs.”

Alamar’s proprietary Attobody™ platform produces a highly diverse pool of antibodies with single digit picomolar affinity and exquisite specificity. Compared to traditional antibody engineering, the Attobody platform deploys an accelerated antibody design and engineering process to generate novel antibodies without the need for affinity maturation.

Newsletter Subscription

Stay informed of the latest news and features